WEBULL
WebtradeDownload

How Investors May Respond To PROCEPT BioRobotics Stock As Revenue Guidance Holds

Simply Wall St · 22h ago
  • PROCEPT BioRobotics reported third quarter 2026 sales of US$98.29 million and a net loss of US$26.52 million, with nine month sales of US$275.92 million and a loss of US$85.02 million, and reaffirmed its 2026 revenue outlook of US$390 million to US$410 million.
  • The results show PROCEPT BioRobotics pairing higher reported sales with wider losses. This keeps attention firmly on how spending, pricing and procedure volumes interact under its reiterated full year revenue range.
  • The focus now turns to how this combination of rising sales and reaffirmed revenue guidance may influence the existing PROCEPT BioRobotics investment narrative.
Spot opportunities across surgical robotics and automation by scanning the 86 robotics and automation stocks. These are already showing strong procedure momentum and attracting growing hospital demand.

PROCEPT BioRobotics Investment Narrative Recap

To keep owning PROCEPT BioRobotics, you need to believe the AquaBeam and HYDROS systems can keep gaining procedure share while the company steadily narrows losses. The latest quarter supports that demand is still there, with higher sales alongside a reaffirmed full year revenue range. The near term catalyst stays the same. Investors are watching whether procedure growth keeps tracking that outlook.

The biggest near term risk remains the widening losses and the fact PROCEPT BioRobotics is still not expected to reach profitability over the next three years. If operating costs keep rising faster than sales, the focus may shift from scaling a category to funding a business that needs more capital before turning the corner.

The most relevant data point for that thesis is the reiterated 2026 revenue guidance of US$390 million to US$410 million. That range indicates management still sees enough hospital demand to support strong full year growth compared with last year. According to Betsareoff, an investor in the Simply Wall St Community, procedure volume is the key metric to track, not short term share price swings.

Betsareoff argues that as long as PROCEPT BioRobotics keeps converting demand into reported procedures and revenue, market volatility around the stock is noise. The current guidance update aligns with that view because it connects the catalyst, procedure momentum, to a concrete revenue band, while highlighting the execution risk if future quarters fall short of those levels.

Betsareoff frames a fair value of US$60.00 per PROCEPT BioRobotics share as reasonable if the business delivers 39.1% a year revenue growth and eventually reaches a 12.9% future profit margin, which together support materially higher earnings power than what current financials reflect.

Uncover why PROCEPT BioRobotics' fair value indicates a 155% potential upside to its current price that may not last much longer.

NasdaqGM:PRCT 1-Year Stock Price Chart
NasdaqGM:PRCT 1-Year Stock Price Chart

Exploring Other Perspectives

One alternate angle on PROCEPT BioRobotics emphasizes litigation risk rather than procedure momentum. The most optimistic analysts were still modeling revenue of about US$648.2 million and earnings of roughly US$81.5 million by 2029 before this quarter, even while warning that class action outcomes could reshape those expectations. Use this earnings update to compare those contrasting views.

Explore 6 other PROCEPT BioRobotics fair value estimates, including one that suggests potential upside of up to 155% from the current price.

Decide For Yourself

Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

Looking For More Investment Ideas Beyond PROCEPT BioRobotics?

If the PROCEPT BioRobotics story has sharpened your thinking and you want to pressure test that framework on other opportunities, the Simply Wall St Screener can help you quickly sort through thousands of companies using the same fundamentals first lens.